Walden (R-OR), Brady (R-TX), Collins, Doug (R-GA), Foxx (R-NC) – Amendment No. 1 - An amendment in the nature of a substitute, which include bipartisan provisions related to (1) Medicare Parts B & D, (2) drug price transparency, (3) Medicare Part D benefit redesign and other Part D provisions, (4) MedPAC, (5) Medicaid, (6) FDA (including CREATES Act; Pay-for-delay; BLOCKING Act; Purple Book; Orange Book; Advancing education on biosimilars; Streamlining transition of biological products; OTC monograph safety, innovation, and reform; and other provisions), (7) revenue provisions, and (8) other bi-partisan provisions
Tonko (D-NY) – Amendment No. 2 - Requires CMS to create and implement a measure in the Star Ratings program evaluating Medicare Advantage and Part D plans on how well they provide access to biosimilar drugs
Peters (D-CA), Cisneros (D-CA) – Amendment No. 3 - To amend the Public Health Service Act to authorize a pilot program to develop, expand, and enhance the commercialization of biomedical products, for other purposes.
Kennedy (D-MA) – Amendment No. 4 - Requires another Senate confirmed officer with HHS to carry out the negotiation duties should the Secretary of HHS have a conflict of interest. The General Counsel of HHS would be responsible for identifying these conflicts
O'Halleran (D-AZ) – Amendment No. 5 - Creates a grant program within HHS for hospitals located in rural and medically underserved areas, including Critical Access Hospitals, to cover the start-up costs for establishing a Graduate Medical Education (GME) program or a partnership with a hospital that has an existing program. It includes a reporting requirement for GAO to analyze whether residents continue to practice in a rural or medically underserved area after completing their training
Kennedy (D-MA) [Offered on behalf of Rep. Jackson Lee] – Amendment No. 6 - Expresses the Sense of Congress regarding the impact of the high cost of prescription drugs on communities of color and persons living in rural (10 minutes) or sparsely populated areas of the United States.
Gottheimer (D-NJ) – Amendment No. .7 - Requires an HHS study to identify conditions without an FDA-approved treatment where the development of a treatment would fill an unmet medical need for a serious or lifethreatening condition or rare disease. Requires HHS to identify appropriate incentives that would lead to the development of such treatments
Axne (D-IA) – Amendment No. 8 - Establishes a grant program for states to reduce the burdens associated with health care administrative work and reduces HHS administrative costs by 50% over 10 years
Finkenauer (D-IA) – Amendment No. 9 - Requires drug companies to disclose truthful and non-misleading pricing information about prescription drugs and biological products when they advertise these products directly to consumers
Luria (D-VA) – Amendment No. 10 - Makes clear that federal employee health plans are covered by the price reduction provisions of the bill
Cunningham (D-SC) – Amendment No. 11 - Allows the Veteran’s Administration to benefit from Maximum Fair Pricing guidelines
Houlahan (D-PA) [on behalf of Scanlon (D-PA)] – Amendment No. 12 - Increases funding for clinical trials at NIH and bans the use of spread pricing by PBMs as it relates to Medicaid
Print